BACKGROUND AND PURPOSE: Our purpose was to specify the most severely affected brain structures in early treated phenylketonuria regarding volume loss and establish possible correlations between volume loss and plasma levels of phenylalanine (Phe). METHODS: In 31 patients with early treated phenylketonuria and in 27 healthy volunteers, we acquired volumetric MR imaging data. Serum Phe concentrations at different times were measured as well. Semiautomatic volumetric postprocessing of the cerebellum, cerebrum (supratentorial brain tissue), hippocampus, intracranial volume, lateral ventricles, nucleus caudatus, nucleus lentiformis, pons, and thalamus, as well as the two-dimensional extension of the corpus callosum, was performed using the software BRAINS2. For each separate brain structure, the relative differences between the normal and the phenylketonuria group (delta(rel)) were calculated. RESULTS: The cerebrum, corpus callosum, hippocampus, intracranial volume, and pons were significantly smaller in patients with phenylketonuria than in healthy patients. The volume of the lateral ventricles was significantly larger in patients with phenylketonuria than in healthy ones. The most severely affected structures were the pons (delta(rel) = 16%), hippocampus (delta(rel) = 14.5%), cerebrum (delta(rel) = 13%), and corpus callosum (delta(rel) = 10%). No significant differences were found for the basal ganglia, cerebellum, and thalamus. There were no significant correlations found between the volume of any of the different brain structures and the metabolic parameters. CONCLUSION: The most severely affected brain structures in early-treated patients with phenylketonuria regarding volume loss are the cerebrum, corpus callosum, hippocampus, and pons.
BACKGROUND AND PURPOSE: Our purpose was to specify the most severely affected brain structures in early treated phenylketonuria regarding volume loss and establish possible correlations between volume loss and plasma levels of phenylalanine (Phe). METHODS: In 31 patients with early treated phenylketonuria and in 27 healthy volunteers, we acquired volumetric MR imaging data. Serum Phe concentrations at different times were measured as well. Semiautomatic volumetric postprocessing of the cerebellum, cerebrum (supratentorial brain tissue), hippocampus, intracranial volume, lateral ventricles, nucleus caudatus, nucleus lentiformis, pons, and thalamus, as well as the two-dimensional extension of the corpus callosum, was performed using the software BRAINS2. For each separate brain structure, the relative differences between the normal and the phenylketonuria group (delta(rel)) were calculated. RESULTS: The cerebrum, corpus callosum, hippocampus, intracranial volume, and pons were significantly smaller in patients with phenylketonuria than in healthy patients. The volume of the lateral ventricles was significantly larger in patients with phenylketonuria than in healthy ones. The most severely affected structures were the pons (delta(rel) = 16%), hippocampus (delta(rel) = 14.5%), cerebrum (delta(rel) = 13%), and corpus callosum (delta(rel) = 10%). No significant differences were found for the basal ganglia, cerebellum, and thalamus. There were no significant correlations found between the volume of any of the different brain structures and the metabolic parameters. CONCLUSION: The most severely affected brain structures in early-treated patients with phenylketonuria regarding volume loss are the cerebrum, corpus callosum, hippocampus, and pons.
Authors: Vincent A Magnotta; Greg Harris; Nancy C Andreasen; Daniel S O'Leary; William T C Yuh; Dan Heckel Journal: Comput Med Imaging Graph Date: 2002 Jul-Aug Impact factor: 4.790
Authors: Georgianne L Arnold; Catherine J Vladutiu; Russell S Kirby; Eileen M Blakely; Jane M Deluca Journal: J Pediatr Date: 2002-08 Impact factor: 4.406
Authors: Ronald Pierson; Hans Johnson; Gregory Harris; Helen Keefe; Jane S Paulsen; Nancy C Andreasen; Vincent A Magnotta Journal: Neuroimage Date: 2010-06-25 Impact factor: 6.556
Authors: Desiree A White; Lisa Tabor Connor; Binyam Nardos; Joshua S Shimony; Rebecca Archer; Abraham Z Snyder; Asif Moinuddin; Dorothy K Grange; Robert D Steiner; Robert C McKinstry Journal: Mol Genet Metab Date: 2010 Impact factor: 4.797
Authors: Roger J Jou; Thomas W Frazier; Matcheri S Keshavan; Nancy J Minshew; Antonio Y Hardan Journal: Behav Brain Res Date: 2013-04-22 Impact factor: 3.332
Authors: Casey E Krueger; David L Dean; Howard J Rosen; Cathra Halabi; Michael Weiner; Bruce L Miller; Joel H Kramer Journal: Alzheimer Dis Assoc Disord Date: 2010 Jan-Mar Impact factor: 2.703
Authors: Deborah A Bilder; J Kay Noel; Erin R Baker; William Irish; Yinpu Chen; Markus J Merilainen; Suyash Prasad; Barbara J Winslow Journal: Dev Neuropsychol Date: 2016-11-02 Impact factor: 2.253
Authors: Zoë Hawks; Anna M Hood; Dov B Lerman-Sinkoff; Joshua S Shimony; Jerrel Rutlin; Daniel Lagoni; Dorothy K Grange; Desirée A White Journal: Neuroimage Clin Date: 2019-07-02 Impact factor: 4.881